secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001140361-24-030348
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics shareholders approve officer exculpation amendment, elect directors
--------------------------------------------------------------------------------

- All three Class III nominees elected: Thomas Eastling (68.9M for), Renate Parry (69.1M), Rodney Nussbaum (69.1M).
- Advisory vote on executive compensation approved with 69.1M for, 7,487 against.
- Ratification of Grant Thornton as auditor for FY 2024 passed (69.4M for, 7,601 against).
- Amendment to certificate of incorporation extending exculpation to certain officers approved (69.0M for).
- Certificate of amendment filed with Delaware on June 14, 2024, effective immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124030348/0001140361-24-030348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124030348/ef20031213_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-030348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer